Angelina Espinosa Guanzon, MD
Psychiatry · Virginia Beach, VANPI 1669536488
Payments from drug & device makers
Across 1,138 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- Teva Pharmaceuticals USA, Inc.$4K
- Sunovion Pharmaceuticals Inc.$3K
- Otsuka America Pharmaceutical, Inc.$1K
- AbbVie$1K
- E.r. Squibb & Sons, L.L.C.$1K
- plus $7K from 27 others
What the payments were for
- Speaking & faculty fees$1,5868%
- Travel & lodging$1,3256%
- Food & beverage$17,54084%
- Education$5222%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 137 | $3,808 |
| Teva Pharmaceuticals USA, Inc. | 129 | $3,562 |
| Sunovion Pharmaceuticals Inc. | 190 | $2,614 |
| Otsuka America Pharmaceutical, Inc. | 75 | $1,301 |
| AbbVie(2 entities) | 128 | $1,246 |
| E.r. Squibb & Sons, L.L.C. | 66 | $1,223 |
| Neurocrine Biosciences, Inc. | 49 | $795 |
| Vanda Pharmaceuticals Inc. | 41 | $752 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $691 |
| Tris Pharma Inc | 31 | $560 |
| Adamas Pharmaceuticals, Inc. | 36 | $499 |
| Axsome Therapeutics, Inc. | 11 | $422 |
| Supernus Pharmaceuticals, Inc. | 42 | $418 |
| Corium, LLC | 18 | $375 |
| Lundbeck LLC | 22 | $370 |
| Alkermes, Inc. | 16 | $341 |
| Neos Therapeutics, LP | 21 | $318 |
| Ironshore Pharmaceuticals Inc. | 10 | $307 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $223 |
| Noven Therapeutics, LLC | 15 | $207 |
| Bausch Health US, LLC | 8 | $199 |
| Neuronetics, Inc. | 4 | $158 |
| Avanir Pharmaceuticals, Inc. | 8 | $132 |
| Jazz Pharmaceuticals Inc. | 7 | $116 |
| Almatica Pharma LLC | 5 | $74 |
| Idorsia Pharmaceuticals US Inc | 4 | $72 |
| Vertical Pharmaceuticals, LLC | 4 | $46 |
| Shire North American Group Inc | 3 | $43 |
| Biogen | 1 | $24 |
| Harmony Biosciences LLC | 1 | $24 |
| Merck | 1 | $19 |
| Eisai Inc. | 1 | $16 |
| Adlon Therapeutics L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,972 in reported general payments places this provider in the 95th percentile of 884 psychiatry providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 41 | $420,832 |
| IngrezzaValbenazine Tosylate | 17 | $131,185 |
| SpravatoEsketamine Hcl | 53 | $110,687 |
| VraylarCariprazine Hcl | 35 | $52,246 |
| RexultiBrexpiprazole | 12 | $33,648 |
| CaplytaLumateperone Tosylate | 15 | $29,436 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 85 | $20,908 |
| TrintellixVortioxetine Hydrobromide | 27 | $20,238 |
| Paliperidone ErPaliperidone | 17 | $18,611 |
| Lurasidone Hcl | 24 | $8,841 |
| Ziprasidone Hcl | 43 | $7,450 |
| Clomipramine Hcl | 14 | $6,432 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 170 | $6,053 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 45 | $5,042 |
| Divalproex Sodium ErDivalproex Sodium | 73 | $4,254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $3,562 | $420,83241 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $795 | $131,18517 claims |
| Johnson & JohnsonSpravato | $3,808 | $110,68753 claims |
| AbbVieVraylar | $1,246 | $52,24635 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,301 | $33,64812 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $691 | $29,43615 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $223 | $20,23827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 884 psychiatry providers in Virginia.
Other psychiatry in Virginia Beach
- William YetterVirginia Beach$312K
- Mark SchreiberVirginia Beach$29K
- Maria CenzonVirginia Beach$17K
- Jolie HinnenkampVirginia Beach$12K
- Elizabeth KaminVirginia Beach$11K
- Stephen CunninghamVirginia Beach$10K
- Heather RoweVirginia Beach$10K
- Niku SinghFalls Church$2.5M
- David ScheidererRoanoke$2.4M
- Kent McDanielGlen Allen$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.